PubMed

Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.

Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, Coulibaly H, Traore M, Sylla M, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Nov 19. [Epub ahead of print]PMID: 19933171 [PubMed - as supplied by publisher]

Factors associated with virological response to etravirine in non nucleoside reverse transcriptase inhibitor experienced HIV-1 infected patients.

Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; the ANRS AC11 Resistance study group.

Antimicrob Agents Chemother. 2009 Nov 9. [Epub ahead of print]PMID: 19901096 [PubMed - as supplied by publisher]Related articles

Impact of Y143 HIV-1 integrase mutations on resistance to Raltegravir in vitro and in vivo.

Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF.

Antimicrob Agents Chemother. 2009 Nov 9. [Epub ahead of print]PMID: 19901095 [PubMed - as supplied by publisher]Related articles

Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4(+) T cells in patients with chronic HIV-1 infection.

Yamamoto T, Samri A, Marcelin AG, Mitsuki YY, Vincent C, Autran B, Tsunetsugu-Yokota Y.

AIDS. 2009 Nov 13;23(17):2265-75.PMID: 19786846 [PubMed - in process]Related articles

HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome.

Prisant N, Tubiana R, Lefebvre G, Lebray P, Marcelin AG, Thibault V, Rosenblum O, Bonmarchand M, Vauthier-Brouzes D, Golmard JL, Katlama C, Poirot C.

Fertil Steril. 2009 Sep 2. [Epub ahead of print]PMID: 19732875 [PubMed - as supplied by publisher]Related articles

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.

Wirden M, Simon A, Schneider L, Tubiana R, Malet I, Ait-Mohand H, Peytavin G, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Nov;64(5):1087-90. Epub 2009 Aug 27.PMID: 19717396 [PubMed - in process]Related articles

HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.

Mouscadet JF, Arora R, André J, Lambry JC, Delelis O, Malet I, Marcelin AG, Calvez V, Tchertanov L.

J Mol Recognit. 2009 Nov-Dec;22(6):480-94.PMID: 19623602 [PubMed - in process]Related articles

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.

Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG.

AIDS. 2009 Jul 31;23(12):1605-8.PMID: 19487903 [PubMed - indexed for MEDLINE]Related articles

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.

Soulié C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, Canestri A, Brunet C, Murphy R, Katlama C, Calvez V, Marcelin AG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):60-4.PMID: 19390328 [PubMed - indexed for MEDLINE]Related articles

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

Antivir Ther. 2009;14(1):123-9.PMID: 19320246 [PubMed - indexed for MEDLINE]Related articles

Characterization and structural analysis of HIV-1 integrase conservation.

Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.

AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.PMID: 19290031 [PubMed - indexed for MEDLINE]Related articles

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Apr;63(4):795-804. Epub 2009 Feb 16.PMID: 19221102 [PubMed - indexed for MEDLINE]Related articles

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F.

J Antimicrob Chemother. 2009 Mar;63(3):585-92. Epub 2009 Jan 15.PMID: 19147519 [PubMed - indexed for MEDLINE]Related articles

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.

Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF.

Nucleic Acids Res. 2009 Mar;37(4):1193-201. Epub 2009 Jan 7.PMID: 19129221 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.

Wirden M, Lambert-Niclot S, Marcelin AG, Schneider L, Ait-Mohand H, Brunet C, Angleraud F, Amard S, Katlama C, Calvez V.

AIDS. 2009 Jan 2;23(1):95-9.PMID: 19050391 [PubMed - indexed for MEDLINE]Related articles

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.

Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. Epub 2008 Oct 13.PMID: 18852278 [PubMed - indexed for MEDLINE]Related articlesFree article

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.

Soulié C, Malet I, Lambert-Niclot S, Tubiana R, Thévenin M, Simon A, Murphy R, Katlama C, Calvez V, Marcelin AG.

AIDS. 2008 Oct 18;22(16):2212-4.PMID: 18832886 [PubMed - indexed for MEDLINE]Related articles

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

Lambert-Niclot S, Flandre P, Malet I, Canestri A, Soulié C, Tubiana R, Brunet C, Wirden M, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2008 Nov;62(5):905-8. Epub 2008 Sep 1.PMID: 18765410 [PubMed - indexed for MEDLINE]Related articlesFree article

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.

Marcelin AG, Tubiana R, Lambert-Niclot S, Lefebvre G, Dominguez S, Bonmarchand M, Vauthier-Brouzes D, Marguet F, Mousset-Simeon N, Peytavin G, Poirot C.

AIDS. 2008 Aug 20;22(13):1677-9.PMID: 18670231 [PubMed - indexed for MEDLINE]Related articles

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V.

Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. Epub 2008 Jul 14.PMID: 18625773 [PubMed - indexed for MEDLINE]Related articlesFree article